NCT00000795View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 Peptide Immunogen, Multivalent

Trial Locations (1)

21205

Johns Hopkins Univ / Ctr for Immunological Research, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH